<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04858308</url>
  </required_header>
  <id_info>
    <org_study_id>YYPCT_YYC506_301</org_study_id>
    <nct_id>NCT04858308</nct_id>
  </id_info>
  <brief_title>Phase 3 Trial to Evaluate the Efficacy and Safety of YYC506.</brief_title>
  <acronym>Atorf-YOOrct</acronym>
  <official_title>Phase 3 Trial to Evaluate the Efficacy and Safety of YYC506.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yooyoung Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yooyoung Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 3 study to evaluate the effiacay and safety of YYC506&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase 3 study to evaluate the effiacay and safety of YYC506 in patients with complex&#xD;
      dyslipidemia where LDL-C is properly controlled but TG and HDL-C levels are not regulated by&#xD;
      Atorvastatin alone.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 29, 2021</start_date>
  <completion_date type="Anticipated">January 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A multicenter, Double-blind, Randomized, Active-controlled, Double dummy, Parelle-group comparative.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double-blind.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Percent change (%) of non-HDL-C from baseline</measure>
    <time_frame>from baseline at 12 weeks</time_frame>
    <description>non HDL-C = TC - HDL-C</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent change (%) of non-HDL-C</measure>
    <time_frame>from baseline at 4, 8, 14 weeks.</time_frame>
    <description>non HDL-C = TC - HDL-C</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change (%) of lipid parameters</measure>
    <time_frame>from baseline at 4, 8, 12, 24 weeks</time_frame>
    <description>TC, HDL-C, LDL-C, TG</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change (%) of diabetes parameters</measure>
    <time_frame>from baseline at 4, 8, 12, 24 weeks</time_frame>
    <description>FBS, HbA1c, Insulin</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">554</enrollment>
  <condition>Dyslipidemias</condition>
  <arm_group>
    <arm_group_label>Test Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Take both YYC506 and Placebo(Control)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Take both Contral and Placebo(YYC506)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YYC506</intervention_name>
    <description>YYC506</description>
    <arm_group_label>Test Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Control</intervention_name>
    <description>Active control</description>
    <arm_group_label>Control Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YYC506 Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Control Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Control Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Test Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  A man or woman over 19 years old.&#xD;
&#xD;
          -  LDL-C properly controlled, TG, HDL-C is not properly controlled&#xD;
&#xD;
          -  Sign on ICF prior to study participation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of Fibromyalgia, Myopathy etc (CK ≥ 2XULN)&#xD;
&#xD;
          -  Uncontrolled hypo-thyroidism (TSH≥1.5XULN)&#xD;
&#xD;
          -  Severe renal impairemnet (Creainine clearance &lt; 30mL/min) etc.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>17 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hyo-soo Kim, Ph.D</last_name>
    <role>Study Chair</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hyo-soo Kim, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Soo Lim, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Bundang Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Seul Gi Ha, PM</last_name>
    <phone>82-2-6202-7105</phone>
    <email>sgha@yypharm.co.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chonbuk National University Hospital</name>
      <address>
        <city>Cheonju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam-si</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seoul National UniversityHospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 20, 2021</study_first_submitted>
  <study_first_submitted_qc>April 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 26, 2021</study_first_posted>
  <last_update_submitted>April 21, 2021</last_update_submitted>
  <last_update_submitted_qc>April 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

